2023102001857

ÅRSREDOVISNING

för

Seagen Sweden AB

Org.nr. 559327-2791

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2021-07-13 - 2022-12-31

Innehåll **Sida**

- förvaltningsberättelse	2
- resultaträkning	3
- balansräkning	4
- noter	6
- underskrifter	8

Undertecknad styrelseledamot i Seagen Sweden AB intygar härmed, dels att denna kopia av årsredovisningen överensstämmer med originalet, dels att resultat- och balansräkning fastställts på årsstämma den 28 juli 2023.
Stämman beslöt tillika godkänna styrelsens förslag till vinstdisposition.

Stockholm 2023-07-28

Audrey Elizabeth Sherman

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

ÅRSREDOVISNING

för

Seagen Sweden AB

Org.nr. 559327-2791

Styrelsen får härmed avlämna årsredovisning för räkenskapsåret 2021-07-13 - 2022-12-31

Innehåll **Sida**

- förvaltningsberättelse	2
- resultaträkning	3
- balansräkning	4
- noter	6
- underskrifter	8

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

FÖRVALTNINGSBERÄTTELSE

Årsredovisningen är upprättad i svenska kronor, SEK.

Verksamheten

Allmänt om verksamheten

Seagen Sweden AB ansvarar för marknadsföringen av sitt yttersta moderbolags produkter i Sverige. Det yttersta moderbolaget av Seagen Sverige är Seagen Inc., som är ett amerikanskt bioteknikföretag fokuserat på att utveckla och marknadsföra innovativa, bemyndigade monoklonala antikroppsbaserade terapier för behandling av cancer.

Bolaget registrerades hos bolagsverket den 13 juli 2021 och då påbörjades verksamheten. Första räkenskapsåret är förlängt och omfattar 15,5 istället för 12 månader.

Företagets säte är Stockholm.

Väsentliga händelser under räkenskapsåret

Det har inte inträffat några väsentliga händelser under räkenskapsåret.

Flerårsöversikt

	2021/2022*
Nettoomsättning	13 019 199
Resultat efter finansiella poster	673 920
Soliditet (%)	10,34
Balansomslutning	5 161 097
Kassalikviditet (%)	152,57

Definitioner av nyckeltal, se noter

* Räkenskapsåret är förlängt och utgör 15,5 istället för 12 månader.

Förändringar i eget kapital

	Aktiekapital	**Övrigt fritt eget kapital**	**Årets resultat**	**Summa fritt eget kapital**
Belopp vid årets ingång	0	0	0	0
Nyemission	25 000			
Årets resultat			509 112	509 112
Belopp vid årets utgång	**25 000**	**0**	**509 112**	**509 112**

Resultatdisposition

Medel att disponera:	
Årets resultat	509 112
	509 112
Förslag till disposition:	
Balanseras i ny räkning	509 112
	509 112

Beträffande bolagets resultat och ställning i övrigt hänvisas till efterföljande resultat- och balansräkningar med tillhörande noter.

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

RESULTATRÄKNING

	Not	2021-07-13 2022-12-31
Rörelseintäkter, lagerförändringar m.m.		
Nettoomsättning		13 019 199
Summa rörelseintäkter, lagerförändringar m.m.		**13 019 199**
Rörelsekostnader		
Övriga externa kostnader		-2 783 559
Personalkostnader	2	-9 490 378
Summa rörelsekostnader		**-12 273 937**
Rörelseresultat		**745 262**
Finansiella poster		
Övriga ränteintäkter och liknande resultatposter		29 757
Räntekostnader	3	-101 099
Summa finansiella poster		**-71 342**
Resultat efter finansiella poster		**673 920**
Resultat före skatt		**673 920**
Skatter		
Skatt på årets resultat		-164 808
Årets resultat		**509 112**

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

BALANSRÄKNING

	Not	2022-12-31
TILLGÅNGAR		
Omsättningstillgångar		
Kortfristiga fordringar		
Fordringar hos koncernföretag		3 851 666
Övriga fordringar		593 592
Förutbetalda kostnader och upplupna intäkter		16 568
Summa kortfristiga fordringar		**4 461 826**
Kassa och bank		
Kassa och bank		699 271
Summa kassa och bank		**699 271**
Summa omsättningstillgångar		**5 161 097**
SUMMA TILLGÅNGAR		**5 161 097**

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

BALANSRÄKNING

	Not	2022-12-31
EGET KAPITAL OCH SKULDER		
Eget kapital		
Bundet eget kapital		
Aktiekapital		25 000
Summa bundet eget kapital		**25 000**
Fritt eget kapital		
Årets resultat		509 112
Summa fritt eget kapital		**509 112**
Summa eget kapital		**534 112**
Långfristiga skulder		
Skulder till koncernföretag		1 244 244
Summa långfristiga skulder		**1 244 244**
Kortfristiga skulder		
Leverantörsskulder		924 933
Skatteskulder		347 355
Övriga skulder		405 303
Upplupna kostnader och förutbetalda intäkter		1 705 150
Summa kortfristiga skulder		**3 382 741**
SUMMA EGET KAPITAL OCH SKULDER		**5 161 097**

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

NOTER

Not 1 Redovisnings- och värderingsprinciper

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd (BFNAR 2016:10) om årsredovisning i mindre företag.

Tjänste- och entreprenaduppdrag
Företagets intäkter från uppdrag till fast pris redovisas enligt huvudregeln.

Not 2 Medelantal anställda

	2021/2022
Medelantal anställda	
Medelantalet anställda bygger på av bolaget betalda närvarotimmar relaterade till en normal arbetstid.	
Medelantal anställda har varit	2,50

Not 3 Räntekostnader och liknande resultatposter

	2021/2022
Räntekostnader och liknande resultatposter som avser skulder till koncernföretag	-26 950

Ränterkostnaderna beräknas på koncernlån från det yttersta moderblaget Seagen Inc. i USA.

Not 4 Långfristiga skulder

	2022-12-31
Förfaller mellan 2 och 5 år	1 244 244
	1 244 244

Not 5 Väsentliga händelser efter räkenskapsårets slut

Den 13 mars 2023 meddelade Seagen Inc. att de har ingått ett definitivt avtal om att koncernen ska förvärvas av Pfizer. Tillsammans med Pfizer kommer Seagen att skapa ett ledande onkologiföretag som kan påskynda leveransen av livsförändrande cancerterapier till fler patienter över hela världen. Med förbehåll för mottagandet av myndighetstillstånd och tillfredsställelse av andra sedvanliga stängningsvillkor, förväntas förvärvet avslutas i slutet av 2023 eller början av 2024. Fram till att förvärvet slutförs kommer Seagen Inc. och Seagen Sweden att fortsätta att fungera och bedriva verskamheten som en oberoende organisation.

Not 6 Koncernförhållanden

Bolaget är helägt dotterbolag till Seagen B.V., Org. nr 000041779711, säte i Evert van de Beekstraat 1-104, 1118 CL Schiphol, Nederländerna.
Övergripande koncernredovisning upprättas av Seagen Inc., org. nr. 2774177, säte i 21823 30 Drive Southeast, Bothell, WA 98021, USA.

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

NOTER

Not 7 Definition av nyckeltal

Soliditet
Justerat eget kapital i procent av balansomslutning

Kassalikviditet
Omsättningstillgångar exkl. varulager i procent av kortfristiga skulder

DocuSign Envelope ID: DE550382-96CA-4BB4-BEF5-A17815B25EEC

Seagen Sweden AB
Org.nr. 559327-2791

Stockholm
2023-07-28

DocuSigned by:
Audrey Sherman
65E6ECBA0837412...

Audrey Elizabeth Sherman

DocuSigned by:
Severine Lemoine
5D265B6B55864DE...

Séverine Quéniart ép. Lemoine

DocuSign

Certificate Of Completion

Envelope Id: DE55038296CA4BB4BEF5A17815B25EEC | Status: Completed

Subject: Complete with DocuSign: Minutes AGM by correspondence - Seagen Sweden AB.docx, 06 Årsredovisnin...

default:

SystemName:

Source Envelope:

Document Pages: 19 | Signatures: 6 | Envelope Originator:

Certificate Pages: 5 | Initials: 0 | Autumn Anderson

AutoNav: Enabled | 21823 30th Dr SE

EnvelopeId Stamping: Enabled | Bothell, WA 98021

Time Zone: (UTC-08:00) Pacific Time (US & Canada) | autanderson@seagen.com

IP Address: 163.116.249.90

Record Tracking

Status: Original
7/28/2023 8:47:23 AM

Holder: Autumn Anderson
autanderson@seagen.com

Location: DocuSign

Signer Events	Signature	Timestamp
Audrey Sherman asherman@seagen.com Vice President, Tax Security Level: Email, Account Authentication (None)	DocuSigned by: Audrey Sherman 65E6ECBA0837412... Signature Adoption: Pre-selected Style Using IP Address: 68.109.73.21	Sent: 7/28/2023 8:52:52 AM Viewed: 7/28/2023 8:54:05 AM Signed: 7/28/2023 8:54:20 AM
Electronic Record and Signature Disclosure: Accepted: 7/28/2023 8:54:05 AM ID: bd50ac44-a54f-42cc-af3e-039e23d56b59		
Marcel Koopman mkoopman@seagen.com General Manager Seagen BV Security Level: Email, Account Authentication (None)	DocuSigned by: A113489FC21145A... Signature Adoption: Drawn on Device Using IP Address: 163.116.181.24	Sent: 7/28/2023 8:52:53 AM Viewed: 7/28/2023 10:36:32 AM Signed: 7/28/2023 10:36:40 AM
Electronic Record and Signature Disclosure: Accepted: 7/28/2023 10:36:32 AM ID: e2a02704-ec90-49a0-8720-60137ec33a07		
Severine Lemoine slemoine@seagen.com General Manager, France Seagen Security Level: Email, Account Authentication (None)	DocuSigned by: Severine Lemoine 5D265B6B55864DE Signature Adoption: Pre-selected Style Using IP Address: 92.184.112.25 Signed using mobile	Sent: 7/28/2023 8:52:53 AM Viewed: 7/28/2023 9:34:24 AM Signed: 7/28/2023 9:35:33 AM
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
In Person Signer Events	**Signature**	**Timestamp**
Editor Delivery Events	**Status**	**Timestamp**
Agent Delivery Events	**Status**	**Timestamp**
Intermediary Delivery Events	**Status**	**Timestamp**

Certified Delivery Events	Status	Timestamp
Carbon Copy Events	**Status**	**Timestamp**
Witness Events	**Signature**	**Timestamp**
Notary Events	**Signature**	**Timestamp**

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	7/28/2023 8:52:53 AM
Certified Delivered	Security Checked	7/28/2023 9:34:24 AM
Signing Complete	Security Checked	7/28/2023 9:35:33 AM
Completed	Security Checked	7/28/2023 10:36:40 AM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Seagen Inc. (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Seagen Inc.:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:
To contact us by email send messages to: servicedesk@seagen.com

To advise Seagen Inc. of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at servicedesk@seagen.com and in the body of such request you must state: your previous email address, your new email address. To change your email address please provide your current email address, full name and new email address you are requesting it to be changed to. Please also indicate that the request is in regards to changing email within Seattle Genetics DocuSign

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Seagen Inc.

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to servicedesk@seagen.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Seagen Inc.

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to servicedesk@seagen.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Seagen Inc. as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Seagen Inc. during the course of your relationship with Seagen Inc..